PubMed Health⌕ Search

PubMed · 10959917

Modeling pharmacokinetic data using heavy-tailed multivariate distributions.

Abstract

Pharmacokinetic studies of drug and metabolite concentrations in the blood are usually conducted as crossover trials, especially in Phases I and II. A longitudinal series of measurements is collected on each subject within each period. Dependence among such observations, within and between periods, will generally be fairly complex, requiring two levels of variance components, for the subjects and for the periods within subjects, and an autocorrelation within periods as well as a time-varying variance. Until now, the standard way in which this has been modeled is using a multivariate normal distribution. Here, we introduce procedures for simultaneously handling these various types of dependence in a wider class of distributions called the multivariate power exponential and Student t families. They can have the heavy tails required for handling the extreme observations that may occur in such contexts. We also consider various forms of serial dependence among the observations and find that they provide more improvement to our models than do the variance components. An integrated Ornstein-Uhlenbeck (IOU) stochastic process fits much better to our data set than the conventional continuous first-order autoregression, CAR(1). We apply these models to a Phase I study of the drug, flosequinan, and its metabolite.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J K Lindsey, B Jones. 2000. Modeling pharmacokinetic data using heavy-tailed multivariate distributions.. https://doi.org/10.1081/bip-100102500

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?

Much has been written recently about low productivity in the pharmaceutical industry and the high cost of drug development. Over a 10-year period ending in 2000, only approximately 11% of compounds tested in humans across 10 large pharmaceutical companies were eventually approved for marketing in the United States and/or Europe. Attrition was highest during phase II (62%) but still significant in phase III (45%) and at the time of registration (23%). Clearly, given the high cost and time required for clinical development, these late-stage failures are unsustainable.

Clinical Trials, Phase I as Topic↗

Transgenic probiotica as drug delivery systems: the golden bullet?

Functional human proteins are constitutively produced in genetically modified bacteria that survive on human mucosal surfaces, to the benefit of the host. The successful Phase I clinical trial with IL-10-producing Lactococcus lactis for Crohn's disease has opened new avenues for the use of transgenic bacteria as delivery vehicles. The major advantage of this novel strategy is the avoidance of systemic side effects associated with conventional therapies. This methodology opens up an alternative method for local delivery of therapeutic proteins to various mucosal tissues.

Clinical Trials, Phase I as Topic↗

Escalation, group and A + B designs for dose-finding trials.

In this paper, rules are given on how to construct escalation, A + B, and group designs for dose-finding trials. Operational characteristics of these designs are discussed and compared via simulations. Dose-finding designs for trials with ordinal toxicity outcome are considered.

Clinical Trials, Phase I as Topic↗